22 February 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has received notification that on 21 February 2024, Jeremy Skillington, Chief Executive Officer of the Company, purchased 154,764 ordinary shares at a price of 10.8 pence per share (the “Purchase”).
Cathal Friel, Chairman said: Both Jeremy and I have been delighted to increase our holdings in Poolbeg in the past number of days, we are both great believers in Poolbeg’s potential and our ability to repeat the success of Amryt Pharma, with a focus upon developing sustainable and profitable revenues over a relatively short period of time.
We have made excellent progress since IPO in building a highly attractive pipeline of high value programmes including POLB 001, which has a market opportunity of over $10 billion. With an industry leading team in place to execute, we are well placed to accelerate the growth of the Company and to generate value for shareholders.
Following the Purchase, Jeremy holds 873,497 ordinary shares representing approximately 0.17 per cent of the Company’s issued share capital.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (as implemented into English law) (“MAR”). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
Enquiries
|
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O’Connell, CFO
|
+44 (0) 207 183 1499
|
If anyone reads this article found it useful, helpful? Then please subscribe
www.share-talk.com or follow
SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned
